Complete response of metastatic renal cancer with dendritic cell vaccine
AUTOR(ES)
Dall'Oglio, Marcos, Srougi, Miguel, Barbuto, José A.M.
FONTE
International braz j urol
DATA DE PUBLICAÇÃO
2003-12
RESUMO
INTRODUCTION: We report a case of metastatic renal cell carcinoma that presented involution following therapy with dendritic cells. CASE REPORT: Male, 51-year old patient underwent left radical nephrectomy in September 1999 due to renal cell carcinoma, evolved with recurrence of the neoplasia in January 2002, confirmed by resection of the lesion. A vaccine therapy based on dendritic cells was then performed during 5 months (4 applications). After this period, there was occurrence of new lesions, whose resection revealed areas of necrosis and inflammatory infiltrate. DISCUSSION: The outcome of renal cell carcinoma is influenced by prognostic factors that confer more aggressive tumor characteristics. However, in cases of recurrence, the systemic therapy with dendritic cells-based vaccine can be associated with a better outcome with regression of disease.
Documentos Relacionados
- Early experience with targeted therapy and dendritic cell vaccine in metastatic renal cell carcinoma after nephrectomy
- Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response.
- Complete androgen blockade for metastatic prostate cancer.
- Clinical response in Japanese metastatic melanoma patients treated with peptide cocktail-pulsed dendritic cells
- Prognostic significance of the dynamic changes of systemic inflammatory response in metastatic renal cell carcinoma
